Nivolumab Alone, With Ipilimumab Maintains Improved Outcomes in Advanced Melanoma in Long-Term Follow-Up
Source: OncLive, June 2021
Nivolumab (Opdivo) monotherapy or in combination with ipilimumab (Yervoy) continued to show durable improvements in overall survival (OS) compared with ipilimumab alone in patients with previously untreated advanced melanoma, according to 6.5 years of follow-up from the phase 3 CheckMate-067 trial that were presented during the 2021 ASCO Annual Meeting.1,2
